Industry forum: Progress in pursuit of therapeutic A2A antagonists - The adenosine A2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  Kase, Hiroshi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; DOPAMINE 2 RECEPTOR; ISTRADEFYLLINE; LEVODOPA; 4 AMINOBUTYRIC ACID; ADENOSINE A2A RECEPTOR; ANTIPARKINSON AGENT; OXIDOPAMINE; PURINE DERIVATIVE;

DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DYSKINESIA; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CORPUS STRIATUM; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; GLOBUS PALLIDUS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; NERVE CELL; PARKINSONISM; PRIMATE; RAT; STATISTICS;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DYSKINESIA, DRUG-INDUCED; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; HUMANS; LEVODOPA; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PRIMATES; PURINES; RATS; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2;

EID: 0344738697     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095219.22086.31     Document Type: Review

References (31)

1. 2A receptor in basal ganglia. Biosci Biotechnol Biochem 2001;65:1447-1457.
2. Kase H, Richardson P, Jenner P, ed. Adenosine Receptors and Parkinson's Disease. San Diego: Academic Press, 2000.
3. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau E. Action of caffeine in the brain with special reference to dependence. Pharmacol Rev 1999;51:83-133.
4. 2 antagonists. J Med Chem 1992;35:2342-2345.
5. 2A receptor antagonist. Eur J Pharmacol 1994;267:335-341.
6. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344.
7. 2A antagonists with potent anti-cataleptic activity. Bio Med Chem Lett 1997;7:2349-2352.
8. 2A receptor antagonist, KW-6002. Seikagaku 2002;74:P663. Abstract.
9. 2A receptor antagonist KW-6002 and its effect on gene expression in the rat brain. Brain Res 2002;953:119-125.
10. 3H] CGS21680. Eur J Pharmacol 1989;168:24-26.
11. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991;57:1062-1067.
12. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999;147:90-95.
13. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-parkinsonian rats. Eur J Pharmacol 2000;408:249-255.
14. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
15. 2 dopamine agonists increases antiparkisonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-327.
16. 2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-1677.
17. 2A receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 1996;16:605-611.
18. A-mediated IPSCs in the rat globus pallidus. J Physiol 2001;532:423-434.
19. 2A receptor enhances GABAergic synaptic transmission via cAMP dependent mechanism in the rat globus pallidus. Br J Pharmacol 2002;136:296-302.
20. 2A receptor antagonist decreases GABA release from rat globus pallidus increased by nigrostriatal lesions: a microdialysis study. Neuroscience 2000;100:53-62.
21. 2A antagonists for a novel therapy in Parkinson's disease. Neurology 2002;(suppl):S44-S48.
22. DeLong MR. Primate model of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
23. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23(suppl):S8-S19.
24. 2A receptors in the rat central nervous system. J Comp Neurol 1998;401:163-189.
25. 2A receptor antagonist. J Neurosci 2000;20:5848-5852.
26. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
27. 2 receptors. Nature 1995;377:424-428.
28. 2 receptor knockout mice. Proc Natl Acad Sci USA 2001;98:1970-1975.
29. Hubble J, Hauser J, Kyowa 6002-US-001 Study Group. A novel adenosine antagonist (KW-6002) as a treatment for advanced Parkinson's disease (PD) with motor complications. Neurology 2002;54(suppl 6):S21. Abstract.
30. 2A antagonist treatment of Parkinson's disease. Neurology 2002;54(suppl 6):P06. Abstract.
31. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002;80:262-270.